Iovance Biotherapeutics (IOVA) 10-Q2017 Q1 Quarterly report

Filed: 3 May 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: aforementioned, Alliance, Anderson, announced, arm, AstraZeneca, attention, attorney, blank, calculation, capacity, case, cGMP, check, checkpoint, civil, Codification, counsel, coverage, damage, DeSilvio, desired, disease, dismissal, disqualify, dissolution, distract, District, divert, dollar, dosing, driven, durvalumab, eliminated, Elma, equipment, establish, exceed, exploit, extracted, false, firm, formula, fourth, Freight, functional, Geleen, GmbH, grown, growth, Handelman, headcount, Hillsberg, inactive, incorporated, incorporation, IND, infrastructure, inhibitor, intercompany, invention, Kuc, Leonard, liquidity, litigation, MedImmune, Michael, misleading, Moffit, motion, negatively, Nevada, nivolumab, Northern, Opdivo, opportunity, owing, par, pari, passu, PC, perpetual, PharmaCell, plaintiff, pro, processed, progressed, Promotion, purported, rata, realized, regimen, reliance, reputation, SAA, Sanford, shareholder, Shortly, stayed, Strategic, subsidiary, substantial, suitable, supply, test, theIn, therapeutically, tissue, titledIn, titledSolomon, TroyGould, unfavorable, unilaterally, unmodified, unrecognized, unreimbursed, unrelated, violated, violation, winding, withdraw, written

Removed: acquired, annually, assured, ASU, body, Branch, carrying, category, colorectal, cooperative, credit, culture, depending, developed, discount, financing, forfeiture, framework, generating, group, growing, hand, hiring, important, imputed, informed, infusing, initiation, invested, investing, killing, kind, laboratory, lapse, manufacturer, modified, offering, ovarian, performing, permitted, planned, practical, premium, proliferate, proprietary, publicly, rapidly, rate, reaching, recognition, record, represented, requiring, resolve, retrospective, role, scale, schedule, standard, subpoena, Surgery, titled, transition, underwritten, vary, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

IOVA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Lion Biotechnologies, Inc. (the “Company”) for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Maria Fardis, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 3, 2017	By:	/s/ Maria Fardis
		Maria Fardis
		Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.